Home・Aktien・DexCom Inc

DexCom Inc

Geschlossen

BrancheGesundheitswesen

86.95 -0.29

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

85.87

Max

87.73

Schlüsselkennzahlen
By Trading Economics
Einkommen	50M 249M
Verkäufe	117M 1.3B
KGV Branchendurchschnitt	34.51 68.51
EPS	0.7
Gewinnspanne	19.039
Angestellte	11,000
EBITDA	52M 389M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+3.68% upside

Dividenden
By Acuity
Nächstes Ergebnis	29. Okt. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	4.6B 33B
Vorheriger Eröffnungskurs	87.24
Vorheriger Schlusskurs	86.95

Nachrichtenstimmung

By Acuity

21%

79%

64 / 340 Ranking in Healthcare

DexCom Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

DexCom Inc Prognose

Kursziel

By TipRanks

3.68% Vorteil

12-Monats-Prognose

Durchschnitt 90.52 USD 3.68%

Hoch 112 USD

Tief 64 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für DexCom Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

23 ratings

Buy

Halten

Sell

Basierend auf 23 Analysten, die in den letzten 3 Monaten Aktienbewertungen für DexCom Inc – Dist abgegeben haben.

Stimmung

By Acuity

64 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.